Document:

ex4_1.htm

    
      

    

    Exhibit 4.1

    
 

    
      		 
      	
              ROSS
      MILLER

              Secretary
      of State

              204
      North Carson Street, Suite 1

              Carson
      City, Nevada 89701-4520

              (775)
      684 5708

              Website:
      www.nvsos.gov

            

    

    

    
      	
               

               

              Certificate
      of Designation

              (PURSUANT
      TO NRS 78.1955)

               

               

            	
               

            

    

    

    
      	
              USE
      BLACK INK ONLY - DO NOT HIGHLIGHT

            	
              ABOVE
      SPACE IS FOR OFFICE USE ONLY

            

    

    

    Certificate
of Designation For

    Nevada
Profit Corporations

    (Pursuant
to NRS 78.1955)

    1.  Name
of corporation:

    

    NANOVIRICIDES,
INC.

    

    2.  By
resolution of the board of directors pursuant to a provision in the articles of
incorporation this certificate establishes the following regarding the voting
powers, designations, preferences, limitations, restrictions and relative rights
of the following class or series of stock.

    

    CERTIFICATE
OF DESIGNATION, RIGHTS AND PREFERENCES

    OF

    SERIES A
CONVERTIBLE PREFERRED STOCK

    OF

    NANOVIRICIDES,
INC.

    

    1.           Designation. The
designation of the series of preferred stock created hereby shall be "Series A
Convertible Preferred Stock" (the "Series A Preferred Stock") and the number of
shares constituting the Series A Preferred Stock shall be 7,000,000 shares, par
value $0.001 per share.

    

    (balance
attached)

    

    3.  Effective
date of filing: (optional)

    
      	 	
              (must
      not be later than 90 days after the certificate is
  filed)

            

    

    4.  Signature:
(required)

     

    
      	
              /s/
      Eugene Seymour,

            	 
      

    

    Signature
of Officer

     

    Filing
Fee: $175.00

     

    IMPORTANT: Failure to include
any of the above information and submit with the proper fees may cause this
filing to be rejected.

     

    
      	
              This
      form must be accompanied by appropriate fees.

            	
              Nevada
      Secretary of State Stock Designation

              Revised:
      3-6-09

            

    

    

    
      
        
           

        

        
          1

          
            

          

        

        
           

        

      

    

    

    CERTIFICATE
OF DESIGNATION, RIGHTS AND PREFERENCES

    OF

    SERIES
A CONVERTIBLE PREFERRED STOCK

    OF

    NANOVIRICIDES,
INC.

    

    (Continued)

    

    2.           Certain Definitions.
For the purposes of the Certificate of Designation, Preferences and Rights which
embodies this resolution, unless the context otherwise requires, capitalized
terms used and not otherwise defined in such Certificate of Designation,
Preferences and Rights shall have the following meanings (with terms defined in
the singular having comparable meanings when used in the plural):

     

    “Additional
Shares of Common Stock” shall mean all shares (including treasury shares) of
common stock issued or sold by the Company after the date hereof, whether or not
subsequently reacquired or retired by the Company, other than (i) shares of
common stock issued upon conversion of the Series A Preferred Stock or (ii)
shares of common stock issued concurrently with the issuance of the Series A
Preferred Stock.

    

    “Business
Day” shall mean any day on which banks are open for business in New York, New
York (other than a Saturday or Sunday), provided that any reference to “days”
(unless Business Days are specified) shall mean calendar days.

    

    “Commission”
shall mean the Securities and Exchange Commission or any successor federal
agency having similar powers.

    

    “Common
Stock” shall mean the common stock of the Company, par value $.001 per share,
and any stock into which such stock shall have been converted or changed or any
stock resulting from any reclassification of such stock and all other stock of
any class or classes (however designated) of the Company, the holders of which
shall have the right, without limitation as to amount, either to all or to a
share of the balance of current dividends and liquidating dividends after the
payment of dividends and distributions on any shares entitled to
preference.

    

    “Company”
shall mean NanoViricides, Inc., a Nevada corporation.

    

    “Conversion
Rate” shall mean the conversion rate set forth in Section 5.

    

    “Convertible
Security” shall mean with respect to the Company any evidence of indebtedness,
shares of stock (other than Common Stock) or other securities directly or
indirectly convertible into or exchangeable for Additional Shares of Common
Stock.

    

    
“Exchange
Act” shall mean the Securities Exchange Act of 1934, as amended.

    

    “Holder”
shall mean a holder of the Series A Preferred Stock.

    

    “Intellectual
Property” shall mean all of the patents, patent applications, provisional patent
applications, and other proprietary intellectual property granted to the
Company.

    

    “Options”
shall mean rights, options or warrants subscribe for, purchase or otherwise
acquire Additional Shares of Common Stock or Convertible
Securities.

    

    
      
        
           

        

        
          2

          
            

          

        

        
           

        

      

    

    

    “Other
Securities” shall mean, when referring to the Company, any stock (other than
Company Common Stock) and any other securities of the Company or any other
Person (corporate or otherwise) which the holder of Series A Preferred Stock
shall at any time be entitled to receive, or shall have received, upon
conversion of Series A Preferred Stock, in lieu of or in addition to Common
Stock, or which at any time shall be issuable or shall have been issued in
exchange for or in replacement of Common Stock or Other Securities.

    

    “Securities
Act” shall mean the Securities Act of 1933, as amended.

    

    

    3.           Dividends and
Distributions.  Holders of the Series A Preferred Stock shall
not be entitled to receive dividends.

    

    

    4.           Voting
Rights:

    

     
(a)           Each share
of Series A Preferred Stock shall vote at the rate of four votes per share,
together with the Common Stock, on all matters to which shareholders of the
Company are entitled to vote.

    

     
(b)           Whenever
holders of the Series A Preferred Stock are required or permitted to take any
action by vote, such action may be taken without a meeting on written consent,
setting forth the action so taken and signed by the holders of the Series A
Preferred Stock having not less than the minimum number of votes that would be
necessary to authorize or take such action at a meeting at which all shares of
Series A Preferred Stock entitled to vote thereon were present and
voted.

    

     
(c)           Holders of
the Series A Preferred Stock shall vote together as a separate class on all
matters which impact the rights, value, or ranking of the Common Stock or Series
A Preferred Stock, as provided herein.

    

     
(d)           So long as
any shares of the Series A Preferred Stock are outstanding, the Company shall
not without first obtaining the approval (by vote or written consent, as
provided by law) of a majority of the then outstanding shares of the Series A
Preferred Stock, voting as a separate class, by way of example and not
limitation.:

    

     (i)           adversely
alter or change the rights, preferences, designations or privileges of the
Series A Preferred Stock; or

    

     (ii)          amend
the Company’s Articles of Incorporation of By-laws in a manner that adversely
affects the rights, preferences, designations or privileges of the holders of
the Series A Preferred Stock;

    

    

    5.           Conversion. The
Holder of the Series A Preferred Stock shall have the right to convert (the
“Conversion Rights”) the Series A Preferred Stock into shares of Common Stock
solely upon a “Change of Control” of the Company.

    

     
(a)           Change of Control
Transaction.  For the purposes of this Certificate of
Designation, a Change of Control shall mean the occurrence of any of (a) an
acquisition after the date hereof by an individual or legal entity or “group”
(as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of
effective control (whether through legal or beneficial ownership of capital
stock of the Company, by contract or otherwise) of in excess of 40% of the
voting securities of the Company (other than by means of conversion or exercise
of the Series A Preferred Stock and the Securities issued together with the
Series A Preferred Stock), (b) the Company merges into or consolidates with any
other Person, or any Person merges into or consolidates with the Company and,
after giving effect to such transaction, the stockholders of the Company
immediately prior to such transaction own less than 60% of the aggregate voting
power of the Company or the successor entity of such transaction, (c) the
Company sells or transfers all or substantially all of its Intellectual Property
to another Person and the stockholders of the Company prior to such transaction
own less than 60% of the aggregate voting power of the acquiring entity
immediately after the transaction, or (d) the execution by the Company of an
agreement to which the Company is a party or by which it is bound, providing for
any of the events set forth in clauses (a) through (c) above.  In the
event of a Change in Control, the Company shall deliver a written notice to the
Holder of the Series A Preferred Stock at the Holder’s last known address as set
forth in the Series A Preferred Stock Register, advising the Holder of the
Change in Control (the “Notice”).

    

    
      
        
           

        

        
          3

          
            

          

        

        
           

        

      

    

     

     
(b)           Conversion.  Upon
the earlier to occur of a Change of Control Transaction or the delivery of
Notice by the Company, the Holders of any shares of Series A Preferred Stock
may, at such holder’s option, without any further consideration, at any time
,elect to convert all or any portion of the shares of Series A Preferred Stock
held by such person into a number of fully paid and nonassessable shares of
Common Stock on the basis four share of Common Stock per each share of Series A
Preferred Stock converted, subject to adjustment as set forth herein (the
“Conversion Rate”).  In the event of a liquidation, dissolution or
winding up of the Company, the Conversion Rights shall terminate at the close of
business on the last full day preceding the date fixed for the payment of any
such amounts distributable on such event to the holders of Series A Preferred
Stock.

    

     
(c)           Mechanics of
Conversion.  The conversion of the Series A Preferred Stock
shall be conducted in the following manner:

     

     (i)         
Holder’s Delivery Requirements.  To convert the Series A Preferred
Stock into full shares of Common Stock on any date, the holder thereof shall
transmit by overnight carrier (or otherwise deliver), for receipt on or prior to
5:00 p.m., New York time on such date, to the Company at its then principal
offices, Attention: Chief Financial Officer, the original certificates
representing the shares of Series A Preferred Stock being converted (the
“Preferred Stock Certificates”) and the original, fully-executed notice of
conversion in the form attached hereto as Exhibit A (the “Conversion
Notice”).

     

     (ii)        
Company’s Response. Upon receipt by the Company of the Conversion Notice and the
Preferred Stock Certificates, the Company shall immediately send, via facsimile,
a confirmation of receipt of such Conversion Notice to such holder and the
Company or its designated transfer agent (the “Transfer Agent”), as applicable,
shall, within five (5) business days following the date of receipt by the
Company of the fully executed Conversion Notice and Preferred Stock
Certificates, issue and deliver to the Holder, certificates registered in the
name of the Holder or its designee, representing the number of shares of Common
Stock to which the holder shall be entitled. If the number of shares of Series A
Preferred Stock represented by the Preferred Stock Certificate(s) submitted for
conversion is greater than the number of shares of Series A Preferred Stock
being converted, then the Company shall, as soon as practicable and in no event
later than five (5) business days after receipt of the Preferred Stock
Certificate(s) and at the Company’s expense, issue and deliver to the holder a
new Preferred Stock Certificate representing the number of shares of Series A
Preferred Stock not converted.

     

     (iii)       
Record Holder.
The person or persons entitled to receive the shares of Common Stock issuable
upon a conversion of the Series A Preferred Stock shall be treated for all
purposes as the record holder or holders of such shares of Common Stock from and
after the Conversion Date.

    

    
      
        
           

        

        
          4

          
            

          

        

        
           

        

      

    

    

     
(d)           Reservation of Common
Stock. The Company shall reserve out of its authorized but unissued
shares of Common Stock that number of its shares of Common Stock as shall be
sufficient to effect the conversion of all outstanding shares of the Series A
Preferred Stock.

    

     
(e)           Termination of Rights on
Conversion. All shares of the Series A Preferred Stock converted as
herein provided shall no longer be deemed to be outstanding, and all rights with
respect to such shares, including the rights, if any, to receive dividends,
notices and to vote, shall immediately cease and terminate on conversion, except
only the right of the holders thereof to receive shares of Common Stock in
exchange therefor. Any shares of Series A Preferred Stock so converted shall be
retired and canceled and shall not be reissued, and the Company may from
time-to-time take such appropriate action as may be necessary to reduce the
number of shares of authorized Series A Preferred Stock
accordingly.

    

     (f)          
 Adjustment for
Reclassification, Exchange, or Substitution. If the Common Stock issuable
upon the conversion of the Series A Preferred Stock shall be changed into the
same or a different number of shares of any class or classes of stock, whether
by capital reorganization, reclassification, or otherwise (other than a
subdivision or combination of shares or stock dividend, or a reorganization,
merger, consolidation, change of control, share exchange or sale of assets, as
provided for below), then and in each such event the holder of each share of
Series A Preferred Stock shall have the right thereafter to convert such share
into the kind and amount of shares of stock and other securities and property
receivable upon such reorganization, reclassification, or other change, by
holders of the number of shares of Common Stock into which such shares of Series
A Preferred Stock might have been converted immediately prior to such
reorganization, reclassification, or change, all subject to further adjustment
as provided herein.

    

     (g)           Adjustment for Merger,
Reorganization, Change of Control, etc. In addition to the convertibility
of the Series A Preferred Stock upon a Change of Control, in case of any
consolidation, merger or share exchange of the Company with or into another
corporation or the sale of all or substantially all of the assets of the Company
to another corporation or in the event that there is a Change of Control, then
each share of Series A Preferred Stock shall thereafter be convertible into the
kind and amount of shares of stock or other securities or property to which a
holder of the number of shares of Common Stock of the Company deliverable upon
conversion of such Series A Preferred Stock would have been entitled upon such
consolidation, merger or sale; and, in such case, appropriate adjustment (as
determined in good faith by the Board of Directors) shall be made in the
application of the provisions in this Section 5 set forth with respect to the
rights and interest thereafter of the holders of the Series A Preferred Stock,
to the end that the provisions set forth in this Section 5 (including provisions
with respect to changes in and other adjustments of the Series A Conversion
Rate) shall thereafter be applicable, as nearly as reasonably may be, in
relation to any shares of stock or other property thereafter deliverable upon
the conversion of the Series A Preferred Stock.

    

     (h)           Adjustment to Conversion
Price Due to Stock Split, Stock Dividend, etc. If, prior to the
Conversion of all of the Series A Preferred Stock, (A) the number of outstanding
shares of Common Stock is increased by a stock split, a stock dividend on the
Common Stock, a reclassification of the Common Stock, or the distribution to
holders of Common Stock of rights or warrants entitling them to subscribe for or
purchase Common Stock at less than the then current market price thereof (based
upon the subscription or exercise price of such rights or warrants at the time
of the issuance thereof), the Conversion Price shall be proportionately reduced,
or (B) the number of outstanding shares of Common Stock is decreased by a
reverse stock split, combination or reclassification of shares, the Conversion
Price shall be proportionately increased.  In such event, the Company
shall notify the Transfer Agent of such change on or before the effective date
thereof.

    

    
      
        
           

        

        
          5

          
            

          

        

        
           

        

      

    

     

     (i)           
No Impairment.
The Company will not, by amendment of its Articles of Incorporation or through
any reorganization, transfer of assets, consolidation, merger, share exchange,
dissolution, issue or sale of securities or any other voluntary action, avoid or
seek to avoid the observance or performance of any of the terms to be observed
or performed hereunder by the Company, but will at all times in good faith
assist in the carrying out of all the provisions of this Section 5 and in the
taking of all such action as may be necessary or appropriate in order to protect
the conversion rights of the holders of the Series A Preferred Stock against
impairment.

    

     
(j)           Certificate as to
Adjustments. Upon the occurrence of each adjustment or readjustment of
the Conversion Rate pursuant to this Section 5, the Company at its expense shall
promptly compute such adjustment or readjustment in accordance with the terms
hereof and furnish to each Holder a certificate setting forth such adjustment
and showing in detail the facts upon which such adjustment or readjustment is
based and shall file a copy of such certificate with its corporate records. The
Company shall, upon the written request at any time of any holder of Series A
Preferred Stock, furnish or cause to be furnished to such holder a similar
certificate setting forth (1) such adjustments and readjustments, (2) the
Conversion Rate then in effect, and (3) the number of shares of Common Stock and
the amount, if any, of other property which then would be received upon the
conversion of Series A Preferred Stock. Despite such adjustment or readjustment,
the form of each or all stock certificate representing Series A Preferred Stock,
if the same shall reflect the initial or any subsequent Conversion Rate, need
not be changed in order for the adjustments or readjustments to be valued in
accordance with the provisions of this Certificate of Designation, Preferences
and Rights which shall control.

    

     
(k)           Notice to
Shareholders. If:

    

     (1)          the
Company shall declare a dividend (or any other distribution) on its Common
Stock; or

    

     (2)          the
Company shall declare a special nonrecurring cash dividend or a redemption of
its Common Stock; or

    

     (3)          the
Company shall authorize the granting to all holders of the Common Stock rights
or warrants to subscribe for or purchase any shares of capital stock of any
class or of any rights; or

    

     (4)          the
approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock of the Company (other than a
subdivision or combination of the outstanding shares of Common Stock), any
consolidation or merger to which the Company is a party, any sale or transfer of
all or substantially all of the assets of the Company, or any compulsory share
exchange whereby the Common Stock is converted into other securities, cash or
property; or

    

    (5)           the
Company shall authorize the voluntary or involuntary dissolution, liquidation or
winding-up of the affairs of the Company;

    

    Then the
Company shall cause to be filed at each office or agency maintained for the
purpose of conversion of Series A Preferred Stock, and shall cause to be mailed
to the Holders of the Series A Preferred Stock at their last address as they
shall appear upon the stock books of the Company, at least twenty (20) calendar
days prior to the applicable record or effective date hereinafter specified, a
notice stating (x) the date on which a record is to be taken for the purpose of
such dividend, distribution, redemption, rights or warrants, or if a record is
not to be taken, the date as of which the holders of Common Stock of record to
be entitled to such dividend, distributions, redemption, rights or warrants are
to be determined, or (y) the date on which such reclassification, consolidation,
merger, sale, transfer, share exchange, dissolution, liquidation or winding-up
is expected to become effective, and the date as of which it is expected that
holders of Common Stock of record shall be entitled to exchange their shares of
Common Stock for securities or other property deliverable upon such
reclassification, consolidation, merger, sale, transfer, share exchange,
dissolution, liquidation or winding-up; provided, however, that the failure to
mail such notice or any defect therein or in the mailing thereof shall not
affect the validity of the corporate action required to be specified in such
notice.

    

    
      
        
           

        

        
          6

          
            

          

        

        
           

        

      

    

    

     
(l)           Curative Provision.
If at any time conditions shall arise by reason of action taken by the Company
which in the opinion of the Board of Directors are not adequately covered by the
other provisions hereof and which might materially and adversely affect the
rights of the holders of Series A Preferred Stock (different than or
distinguished from the effect generally on rights of holders of any class of the
Company’s capital stock) or if at any time any such conditions are expected to
arise by reason of any action contemplated by the Company, the Company shall
mail a written notice briefly describing the action contemplated and the
material adverse effects of such action on the rights of the holders of the
Series A Preferred Stock at least thirty (30) calendar days prior to the
effective date of such action, and an appraiser selected by the holders of a
majority in interest of the Series A Preferred Stock shall give its opinion as
to the adjustment, if any (not inconsistent with the standards established in
this Section 5) of the Conversion Rate (including, if necessary, any adjustment
as to the securities into which shares of Series A Preferred Stock may
thereafter be convertible) and any distribution which is or would be required to
preserve without diluting the rights of the holders of shares of Series A
Preferred Stock; provided, however, that the Company, after receipt of the
determination by such appraiser, shall have the right to select an additional
appraiser, in which case the adjustment shall be equal to the average of the
adjustments recommended by each such appraiser. The Board of Directors shall
make the adjustment recommended forthwith upon the receipt of such opinion or
opinions or the taking of any such action contemplated, as the case may
be.

    

     
(m)           Issuance Taxes. The
issuance of certificates for shares of Common Stock on any conversion of Series
A Preferred Stock shall be made without charge to the holders thereof for any
documentary stamp or similar taxes that may be payable in respect of the issue
or delivery of such certificate, provided that the Company shall not be required
to pay any tax that may be payable in respect of any transfer involved in the
issuance and delivery of any such certificate upon conversion in a name other
than that of the holder of such shares of Series A Preferred Stock so converted
and the Company shall not be required to issue or deliver such certificates or
until the person or persons requesting the issuance thereof shall have paid to
the Company the amount of such tax or shall have established to the satisfaction
of the Company that such tax has been paid.

    

    

    6.           Ranking. For purposes
of the Certificate of Designation, Preferences and Rights embodying this
resolution, any stock of any class or series of the Company shall be deemed to
rank senior to shares of the Series A Preferred Stock, either as to dividends or
upon liquidation, if the holders of stock of such class or series shall be
entitled by the terms thereof to the receipt of dividends or of amounts
distributable upon liquidation, dissolution or winding up, as the case may be,
in preference or priority to the Holder of shares of the Series A Preferred
Stock.

    

    

    7.           Liquidation, Dissolution or
Winding Up. For purposes of the Certificate of Designation, Preferences
and Rights the shares of Series A Preferred Stock shall not be entitled to a
Liquidation Preference with the Common Stock and the other classes of the
Company’s securities upon the liquidation, dissolution, or winding up of the
Company.

    

    
      
        
           

        

        
          7

          
            

          

        

        
           

        

      

    

    

    8.           Miscellaneous
Provisions.

    

     
(a)           Shares Restricted.
Neither the shares of Series A Preferred Stock nor the shares of Common Stock
into which they are convertible have been registered under the United States
Securities Act of 1933, as amended, or applicable state securities laws. Such
securities have been offered, sold and issued pursuant to exemptions from such
laws.

    

     
(b)           Closing of Books. The
Company will at no time close its transfer books against the transfer of any
shares of Series A Preferred Stock or of any share of the Common Stock issued or
issuable upon the conversion of Series A Preferred Stock in any manner which
interferes with the timely conversion of such Series A Preferred
Stock.

    

     
(c)          Headings of
Subdivisions. The headings of the various Sections and other subdivisions
hereof are for convenience of reference only and shall not affect the
interpretation of any of the provisions hereof.

    

     
(d)          Severability of
Provisions. If any voting powers, preferences and relative,
participating, optional and other special rights of the Series A Preferred Stock
and qualifications, limitations and restrictions thereon set forth in the
Certificate of Designation, Preferences and Rights embodying this resolution is
invalid, unlawful or incapable of being enforced by reason of any rule of law or
public policy, all other powers, preferences and relative, participating,
optional and other special rights of Series A Preferred Stock and
qualifications, limitations and restrictions thereon set forth therein which can
be given effect without the invalid, unlawful or unenforceable voting powers,
preferences and relative, participating, optional and other special rights of
Series A Preferred Stock and qualifications, limitations and restrictions
thereon shall, nevertheless, remain in full force and effect, and no voting
powers, preferences and relative, participating, optional or other special
rights of Series A Preferred Stock and qualifications, limitations and
restrictions thereon herein set forth shall be deemed dependent upon any other
such voting powers, preferences and relative, participating, optional or other
special rights of Series A Preferred Stock and qualifications, limitations and
restrictions thereon unless so expressed herein.

    
 

    8ex10_1.htm

    
      

    

    Exhibit 10.1

     

     

    THERACOUR-NANOVIRICIDES
ADDITIONAL LICENSE AGREEMENT

     

     

    This
License Agreement (the "Agreement") is made between TheraCour Pharma, Inc. a
Connecticut corporation (collectively referred to as "TheraCour" or “Theracour”)
and NanoViricides, Inc., a Nevada corporation ("Nano").

     

    BACKGROUND

     

    1.           TheraCour
is engaged in a long-term effort for the research, development and
commercialization of certain proprietary drug delivery and targeting
technologies, including but not limited to the type falling within the scope of
its patent applications, patents, and proprietary products licensed under this
Agreement. TheraCour is entering into this Agreement, in furtherance of such
research, development, and commercialization of its drug delivery and targeting
technologies.

     

    2.           Nano
desires to obtain a license for specific products, to be developed, under such
patents, and patent applications and/or proprietary technologies, to make, have
made, use and sell pharmaceuticals for certain viral diseases, and subject to
certain field, format and other limitations more specifically set forth below,
and TheraCour is willing to grant such a license pursuant to the terms and
conditions set forth herein.

     

    AGREEMENT

     

    NOW,
THEREFORE, in consideration of the above provisions and the mutual covenants
contained herein, the parties agree as follows:

     

    1.          
 Definitions

     

    The
following defined terms shall have the meanings set forth below (with derivative
forms being interpreted accordingly):

     

    1.1           "Affiliate"
shall mean:

     

    
      	
               
      

            	
              1.1.1

            	
              any
      entity that directly or indirectly controls, is controlled by, or is under
      common control with another entity, and for such purpose "control" shall
      mean (a) the possession, direct or indirect, of more than 50 percent of
      the voting power or beneficial interest in the entity, whether through
      ownership of voting securities, by contract or otherwise, or (b) having
      the power to govern the financial or operating policies or to appoint the
      management of the controlled organization, or by (c) contractual or other
      means, the right to participate with, control, direct or otherwise act in
      concert or derive any benefit from the activities of such
      entity.

            

      
        
          
          

        

        
          Page 1 of
14

          
            

          

        

        
           

        

      

    

     

    
      	
               
      

            	
              1.1.2

            	
              any
      entity that directly or indirectly has a minority stock interest in the
      other entity .

            

    

     

    1.2        
  "Calendar Year" shall mean the twelve (12) month period beginning January
1 and ending December 31 in the same year.

     

    1.3           "Effective
Date" shall mean the date this Agreement is executed by the latest signing
party.

     

    1.4           ''End
User" shall mean a person or entity whose use of Licensed Product results in its
consumption, destruction, or loss of activity (in each case, whether whole or
partial).

     

    1.5           "FDA"
shall mean the U.S. Food and Drug Administration and any successor .thereto.

     

    1.6           "Licensed
Product" shall mean any product the manufacture, use or sale of which product
would, in the absence of the license granted to Nano hereunder, infringe a Valid
Patent Claim, Patent Application or a Proprietary Claim covering such
manufacture, use or sale in any of the countries of manufacture, use or sale for
the following viral diseases set forth in the License Grant below.

     

    1.7           "Licensed
Patent" shall mean a claim in a patent or patent application listed in
Exhibit A or that is entitled to the priority of a patent, patent
application, or provisional patent application listed in Exhibit A, or that is
entitled as a claim in a subsequent patent application derived from subject
matter that is further refinement of or substantially inherited from or
disclosed in a patent or patent application or provisional patent application
listed in Exhibit A, including claims in any divisions, extensions,
renewals, reissues, re-examination certificates and continuations of such
patents, patent applications, and provisional patent applications. If a priority
claim is abandoned or lost for any reason including applicable regulatory or
legal time limitations, nevertheless the patent or patent claim that would be
eligible for (i) claiming priority without consideration of any such time
limitations imposed by law, or (ii) exhibiting dependence as derivative from a
patent or patent application or provisional patent application listed in Exhibit
A shall be considered a “Licensed Patent” in this Agreement.

    

    
      
        
          
          

        

        
          Page 2 of
14

          
            

          

        

        
           

        

      

    

     

    1.8           "Ship",
"Shipped" or "Shipment" shall mean the delivery of any unit of Licensed Product
by Nano to a third party for any commercial purpose, except (i) any unit of
Licensed Product for which said third party receives an actual credit for goods
damaged during transit, warranty replacement (excluding expired goods) and
product recalls, (ii) any unit delivered without charge solely for purposes of
preclinical or clinical trials that are required for regulatory approval in that
country and that are conducted prior to the first regulatory approval of the
affected product in that country, and (iii) any unit delivered as free samples
for customer evaluation, up to the maximum number of units permitted for such
purpose.

     

    1.9           "Territory"
shall mean all countries of the world.

     

    1.10          "Third
Party" shall mean any person or entity other than TheraCour and Nano or any of
their respective Affiliates.

     

    1.11          "Valid
Patent Claim" shall mean a claim in any issued or granted, unexpired patent, or
in any patent application or provisional patent application, that is included in
Licensed Products, which claim has not been held unpatentable, invalid or
unenforceable by a non-appealed or unappealable decision by a court or other
appropriate body of competent jurisdiction, or lapsed, become abandoned or
expired. If a pending Valid Patent Claim ceases to be a Valid Patent Claim
because it has gone abandoned, but such pending claim is later revived, then
once it ceases to be abandoned, it shall again qualify as a Valid Patent Claim.
Where elsewhere in this Agreement the phrase "would infringe a Valid Claim" or
similar terminology is used, pending Valid Patent Claims shall be evaluated as
if issued in the country in which such pending Valid Patent Claims are
pending.

     

    1.12          “Proprietary
Claim" shall mean a claim regarding proprietary technologies or confidential
information owned by TheraCour, that is included in or used in the. research,
development, manufacture, packaging, or use of Licensed Products.

     

    1.13          "Claim"
shall mean a Valid Patent Claim or a Proprietary Claim as defined
above.

     

    2.           
  License
Grant. TheraCour hereby grants to Nano a limited, non-transferable.
exclusive license for the use, sale. or offer of sale of the Licensed Product(s)
in the Territory.

    

    
      
        
          
          

        

        
          Page 3 of
14

          
            

          

        

        
           

        

      

    

     

    2.1           Licensed
Products.  The products herein licensed shall include all drugs
developed by TheraCour, for payment by Nano of Costs, Development Fees,
Royalties and other consideration as outlined below, for the treatment of the
following human viral diseases: Dengue Fever type I,II,III & IV; Japanese
Encephalitis; West Nile Virus; Ebola/Marburg; Adenoviral
Conjuntivitis/Keratitis; and Ocular Indications of Herpes Simplex Type 1 & 2
.. The term "virus" shall include all currently medically recognized human viral
strains identified for the specified viruses.

     

    2.2           Additional
Licensed Products:   TheraCour may, but has no obligation
to, license additional developmental products for treatment of additional viral
diseases to Nano, after Nano has developed and commercialized at least one drug
candidate.

     

    2.3           TheraCour
retains the exclusive right to develop and manufacture the aforesaid drugs. As
to any Licensed Product, TheraCour agrees that it will manufacture such drug
exclusively for Nano, and unless such license is terminated, will not
manufacture such product for its own sake or for others. Nano agrees that
TheraCour shall automatically have a license to employ Nano’s proprietary or
patented technologies or other know how for the purpose of manufacturing the
drug as may be required without payment of any consideration therefore, whether
cash or non-cash considerations, irrespective of whether such consideration is
with or without monetary value.

     

    3.           
 Licensing
Fees. Development Fees and Royalties.

     

    In
consideration of TheraCour granting Nano the license herein, Nano agrees to pay
TheraCour the following licensing fees, development fees and
royalties.

     

    3.1           Upon
execution, a licensing fee of 7 million shares of NanoViricides, Inc. Series A
convertible Preferred Stock, the rights of which are set forth in the
Certificate of Designation attached hereto.

     

    3.2           Development
Fee. TheraCour shall be the sole developer of all Licensed Products.
TheraCour shall charge all of its costs, direct costs (as hereinafter defined),
as well as indirect costs, plus a fee equal to thirty (30%) percent of such
direct costs. To the extent not paid pursuant to prior license agreements, Nano
shall further pay to TheraCour a monthly laboratory facilities fee of
$25,000.00. In consideration of such fee, TheraCour shall use all the
nano-materials and chemicals in its existing inventory in the development of the
licensed product(s) as required. The above shall constitute the Development Fee
to be paid to TheraCour.

     

    
      
        
          
          

        

        
          Page 4 of
14

          
            

          

        

        
           

        

      

    

     

    3.2.1         Advance
Payments. TheraCour may request, and Nano agrees to provide, an advance
payment equal to two months of estimated future development costs, as pursuant
to prior agreements.

     

    3.3           Direct
Costs. Direct Costs shall include all salaries and wages including all
payroll taxes, Workers Compensation premiums, employee benefits, consultants
providing services directly related to the development of the licensed
product(s), lab supplies and chemicals, and reasonable and customary charges for
items such as future hazardous materials disposal according to local law and
regulations. The costs may also include the costs for protection of all
intellectual property rights related to the development. Any other costs
incurred during the conduct of the development project will also be charged as
development costs. In addition, to the extent not paid pursuant to prior
agreements, the following monthly amounts of expenses may be billed with no need
for a voucher: Office Supplies ($500); Travel and Entertainment ($500); External
Consultants ($500); and Miscellaneous Expenses ($500) as pursuant to prior
agreement and not in addition. Such Development fees shall be due and payable in
periodic installments as billed, along with advance payments as requested.
Salaries paid to Dr. Anil Diwan and Dr. Jayant Tatake shall not be included as
Development Costs, but such salaries, benefits and other payments shall be
reimbursed in full by Nano.

     

    3.4           Royalties.
Nano shall pay to TheraCour a royalty of 15% on its net sales and other revenue
proceeds of Licensed Products. Net sales are defined as Sales at gross invoice
amounts less any adjustments for returns, allowances, or discounts taken against
the sales and no other adjustments. Other Revenue Proceeds include all revenues
or consideration generated as a result of the development of Licensed Products
or from further licensing by Nano of any rights resulting from the Licensed
Products or Technologies. Both Net Sales and Other Revenue Proceeds shall
include cash as well as non-cash considerations, irrespective of whether such
consideration is with or without monetary value.

     

    3.4           Nano
shall make its best efforts to market and commercialize any Licensed Product
that is approved for marketing or sales in a region of the
Territory.

     

    
      	
               
      

            	
              (i).

            	
              If
      Nano determines not to proceed to do so, then Nano shall promptly notify
      TheraCour as such and TheraCour subsequently shall have all rights to such
      Product including right to market the product or license it to other
      parties provided that TheraCour arranges to pay back the amounts financed
      by Nano for the said product.

            

      
        
          
          

        

        
          Page 5 of
14

          
            

          

        

        
           

        

      

    

     

    
      	
               
      

            	
              (ii).

            	
              If
      Nano fails to market an approved product within a reasonable period of
      time, then TheraCour shall have the right to buy back the rights to the
      said product by arranging to repay the costs financed by Nano for the said
      product.

            

    

     

    3.5           If
Nano decides to terminate the development of any Licensed Product at any stage,
all rights provided to Nano for said product shall reinvest in TheraCour.
TheraCour may declare that Nano has terminated the development of a Licensed
Product by giving a 90 days notice cure (the "Cure period") to Nano if Nano
fails to or refuses to (a) pay the licensing fees in a timely manner, (b) pay
the development costs (including advance payments as specified above) of any
Licensed Product in a timely manner, (c) pay royalties and development costs
when due, or (d) market, sell and/or commercialize the licensed product(s) as
agreed to. Upon the expiration of the cure period the licenses granted herein
for such licensed product are cancelled and void.

     

    3.6           Records:
Reports. Nano shall keep complete and accurate records of the Shipment of
Licensed Products hereunder and other revenue proceeds related to the Licensed
Products hereunder for no less than five (5) years after the time period to
which they relate. Nano shall within 60 days following the end of each calendar
quarter deliver to TheraCour a written report for such period setting forth the
product Shipped, the number of units delivered for preclinical or clinical study
purposes or provided as free samples pursuant to this Agreement and setting
forth the royalties accrued during such period, (specifying with respect to the
quantity of each Licensed Product for sale and other revenue
proceeds).

     

    3.7           Audits.
TheraCour shall have the right to have an independent certified public
accounting firm reasonably acceptable to Nano (such acceptance not to be
unreasonably withheld, delayed or conditioned) audit Nano's Licensed
Product-related records. Nano shall permit such firm access to Nano's records
during reasonable business hours for the purpose of verifying the royalties as
provided for in this Agreement, but no more frequently than once per year. Such
firm shall agree to keep all information received strictly confidential and will
provide to TheraCour only the information necessary to verify
the royalty calculations.  If any
such audit results in a change upward in any royalty payment Nano shall
pay such additional amount, with compound interest. If such additional amount
exceeds 5%, Nano shall additionally pay the costs of such audit
promptly.

     

    3.8           Upon
termination of this agreement for any cause, Nano shall duly account to
TheraCour and shall transfer to TheraCour all rights that it may possess in
contracts, sub-licenses, letters patent, inventions, trade names, and
trademarks, relating to the Licensed Product(s).

     

    
      
        
        

      

      
        Page 6 of
14

        
          

        

      

      
        
        

      

    

     

    4.        
    Payment.

     

    4.1           Currency:
Payment Timing. Except to the extent provided under Paragraph 3.1,
payment of royalties under this Agreement shall be in U.S. Dollars and made
within 30 days following the end of each calendar quarter for royalties accrued
during such period in accordance with Article 3.

     

    4.2           Transfers.
All payments of cash value under this Agreement shall be made by bank wire
transfer to the bank account designated, in writing, by TheraCour and which
shall be authorized to accept payment on behalf of TheraCour. Any late payments
shall bear interest monthly at the lesser of (i) two percent (2%) more than the
prime rate then in effect of Chase Manhattan Bank, New York, New York (or any
successor to Chase, or if Chase ceases to quote such rate and does not have a
successor entity a comparable bank), or (ii) the maximum rate permitted by
applicable law.

     

    5.         
   Representations
and Warranties

     

    5.1           Representations
and Warranties. Theracour and Nano each represent and warrant to the
other that they have the full right and power to enter into this Agreement and
grant the licenses that such parties are granting as set forth in this
Agreement.

     

    5.2.           Disclaimer.
EXCEPT AS SPECIFICALLY SET FORTH IN PARAGRAPH 5.1 HEREIN, NO PARTY MAKES ANY
REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, ARISING BY LAW OR
OTHERWISE, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT WILL ANY PARTY LICENSING
TECHNOLOGY TO THE OTHER PARTY HAVE, AS A RESULT OF SUCH LICENSE, ANY OBLIGATION
OR LIABILITY ARISING FROM TORT, OR FOR LOSS OF REVENUE OR PROFIT, OR FOR
INCIDENTAL OR CONSEQUENTIAL DAMAGES.

     

    In
particular, with no limitation implied, nothing in this Agreement will be
construed as:

     

    
      	
               
      

            	
              1)
      A warranty or representation as to the validity or scope of any of the
      Licensed Products, Patents or Patent
  Applications;

            

    

     

    
      	
               
      

            	
              2)
      A warranty or representation that anything made, used, sold, or otherwise
      disposed of under the licenses granted in this Agreement is or will be
      free from infringement of patents of third
  parties;

            

    

     

    
      
        
          
          

        

        
          Page 7 of
14

          
            

          

        

        
           

        

      

    

    

    
      	
               
      

            	
              3)
      An obligation to or for the licensing parties to bring or prosecute
      actions or suits against third parties for Licensed Patent infringement or
      a right for the Licensed Party to do
so;

            

    

     

    
      	
               
      

            	
              4)
      Conferring the right to use in advertising, publicity, or otherwise any
      trademark, trade name, or any contraction, abbreviation, simulation, or
      adaptation thereof, of another party except to the extent of the licenses
      herein granted; or

            

    

     

    
      	
               
      

            	
              5)
      Except as otherwise provided herein, conferring by implication, estoppel,
      or otherwise, any license or rights under any patents other than as to the
      Licensed Products, or any license under any other property rights, such as
      know-how, clinical data, trademarks or trade
  names.

            

    

     

    6.         
   Term.
Termination

     

    6.1           Term.
This Agreement is in force and effect on and as of the Effective Date, and shall
continue in effect until the expiration of the last to expire of the Patents
underlying the Licensed Products ("last expiration date"), unless earlier
terminated as provided herein. If at said last expiration date, Nano continues
to use any proprietary technologies developed by TheraCour for any of the
Licensed Products, then this agreement will continue to remain in force as long
as Nano continues to use such proprietary technologies of
TheraCour.

     

    6.2           Termination.

     

    
      	
               
      

            	
              6.2.1

            	
              The
      licenses granted to Nano hereunder may be terminated by TheraCour upon
      written notice to Nano in case of (a) the institution by or against Nano
      of insolvency, receivership or bankruptcy proceedings or any other
      proceedings for the settlement of Nano's debts; (b) Nano's making a
      general assignment for the benefit of its creditors; (c) Nano's
      dissolution; (d) Nano's cessation of business for a period of ninety (90)
      days or more; or (e) Nano or any of its Affiliates voluntarily acting or
      assisting others to challenge or invalidate the Licensed Patents in any
      opposition, declaratory judgment or other
  proceedings.

            

    

     

    
      	
               
      

            	
              6.2.2

            	
              Nano
      may terminate this Agreement on 90 days notice to TheraCour, providing it
      pays to said parties all monies due and owing as of the date of such
      notice to terminate, and further providing that it ceases all sales of
      Licensed Products and destroys all stocks of product not otherwise shipped
      and transfers all related documentation to
  TheraCour.

            

    

     

    
      
        
          
          

        

        
          Page 8 of
14

          
            

          

        

        
           

        

      

    

    

    
      	
               
      

            	
              6.2.3

            	
              All
      rights to the Licensed Products and technologies shall revert to TheraCour
      upon termination of the Agreement.

            

    

     

    6.3           Non-Waiver.
Failure to terminate this Agreement following a material breach or failure to
comply with this Agreement shall not constitute a waiver of a party's defenses,
rights or causes of action arising from such or any future breach or
noncompliance.

     

     

    6.4           Survival.
Articles 7 and 8 shall survive any and all expirations and terminations of this
Agreement.

     

    7.          
  Confidential
Information

     

    From time
to time during the term of this Agreement, TheraCour, on the one hand, and Nano,
on the other, may provide to each other information concerning patents, patent
applications, license agreements and other confidential or proprietary
information related to this Agreement and the Licensed Products (the
"Information"). Each party receiving such Information (the ''Receiving Party")
shall during the term of this Agreement and for a period of ten (10) years after
termination hereof: (i) maintain the Information in confidence; (ii) not
disclose the Information or any portion or copy of it to any third party; and
(iii) not use the Information or any portion or copy of it for any purpose not
directly related to performance of its obligations under this Agreement. The
obligations of this Section shall not apply to any Information which is at the
time of disclosure or thereafter becomes generally known to the public by means
other than a breach of a duty by the Receiving Party or a breach of this
Agreement. The Receiving Party shall disclose the Information only to those
officers, employees and agents bound by similar terms of confidentiality to
those imposed on the Receiving Party hereunder. Upon termination of this
Agreement for any reason, the Receiving Party shall return all Information and
copies thereof. The Receiving Party may disclose Information if required to
comply with law or court order; provided, however, that it provides the
Disclosing Party with advance notice of the required disclosure and all
reasonable assistance to seek confidential treatment or a protective
order.

     

    
      
        
          
          

        

        
          Page 9 of
14

          
            

          

        

        
           

        

      

    

     

    8.        
     Miscellaneous

     

    8.1           Severability:
Compliance with Law. In performing this Agreement, the parties shall
comply with all applicable laws. Nothing in this Agreement shall be construed so
as to require the violation of any law, and wherever there is any conflict
between any provision of this Agreement and any law, the law shall prevail and
the provision shall be appropriately adjusted, but in such event the affected
provision of this Agreement shall be adjusted only to the extent necessary to
bring it within the applicable law and accomplish the intent of the
parties.

     

    8.2           Notices.
Any notice, report, demand or other communication required or permitted to be
given by this Agreement shall be in writing in English, and shall be given by
facsimile and by postpaid, first class, registered or certified mail addressed
as set forth below unless changed by notice so given:

     

    
      	
              For
      TheraCour:

            	
              For
      Nano:

            
	
              TheraCour
      Pharma, Inc.

            	
              NanoViricides,
      Inc.

            
	
              135
      Wood Street, Ste. 200

            	
              135
      Wood Street, Ste. 205

            
	
              West
      Haven, CT 06516, U.S.A.

            	
              West
      Haven, CT 06516, U.S.A.

            
	
              Attn:
      Chief Executive Officer

            	
              Attn:
      Chief Executive Officer

            
	
              cc:
      General Counsel

            	
              cc:
      General Counsel.

            

    

     

    8.3           Force
Majeure. No party to this Agreement shall be liable for delay or failure
in the performance of any of its obligations hereunder if such delay or failure
is due to causes beyond its reasonable control or ability to plan for,
including, without limitation, acts of God, fires, earthquakes, strikes and
labor disputes, acts of war, civil unrest or intervention of any governmental
authority, but any such delay or failure shall be remedied by such party as soon
as is reasonably possible, and if such delay or failure last for more than
ninety (90) days, the other party or parties shall be entitled to terminate this
Agreement.

     

    8.4           Assignments.
Nano may not assign its rights and obligations under this Agreement without the
written consent of the other parties hereto. Without limiting the generality of
the foregoing, this Agreement shall inure to the benefit of and be binding on
the permitted assigns, Affiliates and subsidiaries of the parties.

     

    8.5           No
Third Party Beneficiaries. This Agreement is entered into solely for the
benefit of the parties hereto, and the provisions of this Agreement shall be for
the sole and exclusive benefit of such parties. Nothing herein contained will be
deemed to create any third party beneficiaries or confer any benefit or rights
on or to any person not a party hereto, and no person not a party hereto shall
be entitled to enforce any provisions hereof or exercise any rights
hereunder.

     

    8.6           Waivers
and Modifications. The failure of any party to insist on the performance
of any obligation hereunder shall not act as a waiver of such obligation. No
waiver, modification, release or amendment of any obligation under this
Agreement shall be valid or effective unless in writing and signed by duly
authorized officers of each party hereto.

     

    
      
        
          
          

        

        
          Page 10 of
14

          
            

          

        

        
           

        

      

    

     

    8.7           Choice
of Law. This Agreement is subject to and shall be construed and enforced
in accordance with the laws of the state of New York, with giving effect to any
conflict of law principles that would apply the law of another
jurisdiction.

     

    8.8           Dispute
Resolution.

     

    
      	
               
      

            	
              8.8.1

            	
              Any
      controversy or claim arising out of or relating to this Agreement or the
      validity, inducement, or breach thereof, shall be settled by arbitration
      before a single arbitrator in accordance with the commercial Arbitration
      Rules of the American Arbitration Association ("AAA") then pertaining,
      except where those rules conflict with this provision, in which case this
      provision controls. The parties hereby consent to the personal
      jurisdiction of the Federal District Court for the Southern District of
      New York (and to the extent that federal subject matter jurisdiction is
      lacking, to New York state courts within such Southern District) for the
      enforcement of these provisions and the entry of judgment on any award
      rendered hereunder. Should such court for any reason lack jurisdiction,
      any court with jurisdiction shall enforce this clause and enter judgment
      on any award. The arbitrator shall be an attorney specializing in business
      litigation who has at least 15 years of experience with a law firm of over
      25 lawyers or was a judge of a court of general jurisdiction. The
      arbitration shall be held in Manhattan and the arbitrator shall apply the
      substantive law of the State of New York, except that the interpretation
      and enforcement of this arbitration provision shall be governed by the
      Federal Arbitration Act. Within 30 days of initiation of arbitration, the
      parties shall reach agreement upon and thereafter follow procedures
      assuring that the arbitration will be concluded and the award rendered
      within no more than six months from the selection of the arbitrator.
      Failing such agreement, the AAA will design and the parties will follow
      such procedures. Each party has the right before or during the arbitration
      to seek and obtain from the appropriate court provisional remedies such as
      attachment, preliminary injunction, replevin, etc, to avoid irreparable
      harm, maintain the status quo or preserve the subject matter of the
      arbitration. THE ARBITRATOR SHALL NOT AWARD ANY PARTY PUNITIVE, EXEMPLARY
      OR CONSEQUENTIAL DAMAGES, AND EACH PARTY HEREBY IRREVOCABLY WAIVES ANY
      RIGHT TO SEEK. SUCH DAMAGES.

            

      
        
          
          

        

        
          Page 11 of
14

          
            

          

        

        
           

        

      

    

     

    
      	
               
      

            	
              8.8.2

            	
              Nothing
      in this Section 8.8 shall be deemed to preclude a party from bringing suit
      against the other party in a court of competent jurisdiction to enforce,
      or enjoin infringement of, such party's intellectual property
      rights.

            

    

     

    8.9           Headings.
The headings of the sections of this Agreement have been inserted for
convenience of reference only and do not constitute a part of this
Agreement.

     

    8.10          Entire
Agreement. This Agreement constitutes the entire agreement between the
parties as to the subject matter hereof, and all prior negotiations,
representations, agreements and understandings are merged into, extinguished by
and completely expressed by this Agreement.

     

    8.11          Draftsmanship.
This Agreement has been jointly prepared by the parties and shall not be
strictly construed against any of them.

     

    8.12         Counterparts.
This Agreement may be executed in any number of counterparts with the same
effect as if all parties had signed the same document. All such counterparts
shall be deemed an original, shall be construed together and shall constitute
one and the same instrument.

     

    
      IN
WITNESS WHEREOF, the parties have duly executed this Agreement on the date(s)
written below.

       

      
        	
                TheraCour
      Pharma, Inc.

              	
                NanoViricides,
      Inc.

              
	 
      	 
      
	 
      	 
      
	
                By:
      /s/
      Anil Diwan

              	
                By:
      /s/
      Eugene Seymour

              
	
                Name:
      Anil R. Diwan. Ph.D.

              	
                Name:
      Eugene Seymour, M.D.

              
	
                Title:
      Chief Executive Officer

              	
                Title:
      Chief Executive Officer

              
	
                Date: February
      15, 2010

              	
                Date:
      February 15, 2010

              

      

       

    

    
      
        
          
          

        

        
          Page 12 of
14

          
            

          

        

        
           

        

      

    

    

    EXHIBIT
A

     

    LICENSED
PATENTS AND PATENT APPLICATIONS

     

    
      	
              1.

            	
              "SOLUBILIZATION
      AND TARGETED DELIVERY OF DRUGS WITH SELF-ASSEMBLING AMPHIPHILIC
      POLYMERS," as
      described in an Application for Letters Patent of the Unites States of
      America, Application No. PCT/US2006/001820, filed January 19,
      2006.

            

    

     

    
      	
              2.

            	
              "AMPHIPHILIC
      POLYMERIC MATERIALS," as described in Letters Patent of the United States
      of America, Serial No. US 6,521,736, filed February 18,
    2003.

            

    

    
      	
               
      

            	 

    

    
      	
              3.

            	
              “SELF-ASSEMBLING
      AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS,” as described in an Application
      for Letters Patent of the Unites States of America, Application No.
      PCT/US07/01607, filed January 19,
2007.

            

    

    

    
      
        
          
          

        

        
          Page 13 of
14

          
            

          

        

        
           

        

      

    

    

    EXHIBIT
B

     

    CERTIFICATE
OF DESIGNATION

     

     

    Page 14 of
14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]